Checkpoint Therapeutics Inc
Company Profile
Business description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Contact
95 Sawyer Road
Suite 110
WalthamMA02453
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,298.20 | 10.30 | 0.12% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,425.83 | 154.16 | 0.69% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 21,926.26 | 81.85 | -0.37% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 35,902.51 | 62.52 | 0.17% |
| NZX 50 Index | 11,974.35 | 51.10 | -0.42% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,083.30 | 12.70 | 0.16% |
| SSE Composite Index | 3,281.49 | 5.17 | -0.16% |